WO2018162443A1 - Inhibiteurs de bêta-sécrétase - Google Patents

Inhibiteurs de bêta-sécrétase Download PDF

Info

Publication number
WO2018162443A1
WO2018162443A1 PCT/EP2018/055401 EP2018055401W WO2018162443A1 WO 2018162443 A1 WO2018162443 A1 WO 2018162443A1 EP 2018055401 W EP2018055401 W EP 2018055401W WO 2018162443 A1 WO2018162443 A1 WO 2018162443A1
Authority
WO
WIPO (PCT)
Prior art keywords
3alkyl
halo
optionally substituted
3alkyloxy
group
Prior art date
Application number
PCT/EP2018/055401
Other languages
English (en)
Inventor
Ann Marleen VOS
Daniel Oehlrich
Henricus Jacobus Maria Gijsen
Karl Shawn Watts
Sathesh Pangala BHAT
Frans Alfons Maria Van Den Keybus
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority to EP18709999.9A priority Critical patent/EP3592750A1/fr
Priority to CN201880016454.4A priority patent/CN110418793A/zh
Priority to JP2019548602A priority patent/JP2020509068A/ja
Priority to CA3051764A priority patent/CA3051764A1/fr
Priority to AU2018229721A priority patent/AU2018229721A1/en
Priority to US16/489,885 priority patent/US20200010482A1/en
Priority to EA201992076A priority patent/EA201992076A1/ru
Priority to MX2019010649A priority patent/MX2019010649A/es
Priority to KR1020197028598A priority patent/KR20190126345A/ko
Publication of WO2018162443A1 publication Critical patent/WO2018162443A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention relates to tricyclic inhibitors of beta-secretase having the structure shown in Formula I) and (II)
  • the invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease, dementia associated with beta-amyloid, age-related macular degeneration, type 2 diabetes and other metabolic disorders.
  • AD Alzheimer's disease
  • mild cognitive impairment dementia
  • dementia with Lewy bodies dementia with Lewy bodies
  • Down's syndrome dementia associated with stroke
  • dementia associated with Parkinson's disease dementia associated with beta-amyloid
  • age-related macular degeneration type 2 diabetes and other metabolic disorders.
  • AD Alzheimer's Disease
  • AD patients suffer from cognition deficits and memory loss as well as behavioral problems such as anxiety. Over 90% of those afflicted with AD have a sporadic form of the disorder while less than 10% of the cases are familial or hereditary. In the United States, about one in ten people at age 65 have AD while at age 85, one out of every two individuals are afflicted by AD. The average life expectancy from the initial diagnosis is 7-10 years, and AD patients require extensive care either in an assisted living facility or by family members. With the increasing number of elderly in the population, AD is a growing medical concern. Currently available therapies for AD merely treat the symptoms of the disease and include acetylcholinesterase inhibitors to improve cognitive properties as well as anxiolytics and antipsychotics to control the behavioral problems associated with this ailment.
  • Abeta 1-42 beta-amyloid 1-42 (Abeta 1-42) peptide.
  • Abeta 1-42 forms oligomers and then fibrils, and ultimately amyloid plaques. The oligomers and fibrils are believed to be especially neurotoxic and may cause most of the neurological damage associated with AD.
  • Agents that prevent the formation of Abeta 1-42 have the potential to be disease-modifying agents for the treatment of AD.
  • Abeta 1-42 is generated from the amyloid precursor protein (APP), comprised of 770 amino acids.
  • APP amyloid precursor protein
  • Abeta 1-42 The N-terminus of Abeta 1-42 is cleaved by beta-secretase (BACE1), and then gamma-secretase cleaves the C-terminal end. In addition to Abeta 1-42, gamma- secretase also liberates Abeta 1-40 which is the predominant cleavage product as well as Abeta 1-38 and Abeta 1-43. These Abeta forms can also aggregate to form oligomers and fibrils. Thus, inhibitors of BACE1 would be expected to prevent the formation of Abeta 1-42 as well as Abeta 1-40, Abeta 1-38 and Abeta 1-43 and would be potential therapeutic agents in the treatment of AD.
  • BACE1 beta-secretase
  • Type 2 diabetes is caused by insulin resistance and inadequate insulin secretion from pancreatic beta-cells leading to poor blood-glucose control and hyperglycemia.
  • Patients with T2D have an increased risk of microvascular and macrovascular disease and a range of related complications including diabetic nephropathy, retinopathy and cardiovascular disease.
  • the rise in prevalence of T2D is associated with an increasingly sedentary lifestyle and high-energy food intake of the world's population.
  • Tmem27 has been identified as a protein promoting beta-cell proliferation and insulin secretion.
  • Tmem27 is a 42 kDa membrane glycoprotein which is constitutively shed from the surface of beta-cells, resulting from a degradation of the full-length cellular Tmem27.
  • Overexpression of Tmem27 in a transgenic mouse increases beta-cell mass and improves glucose tolerance in a diet-induced obesity DIO model of diabetes.
  • siRNA knockout of Tmem27 in a rodent beta-cell proliferation assay reduces the proliferation rate, indicating a role for Tmem27 in control of beta-cell mass.
  • BACE2 is the protease responsible for the degradation of Tmem27.
  • Inhibitors of BACE1 and/or BACE2 can in addition be used for the therapeutic and/or prophylactic treatment of amyotrophic lateral sclerosis (ALS), arterial thrombosis, autoimmune/inflammatory diseases, cancer such as breast cancer, cardiovascular diseases such as myocardial infarction and stroke, dermatomyositis, Down's Syndrome, gastrointestinal diseases, Glioblastoma multiforme, Graves Disease, Huntington's Disease, inclusion body myositis (IBM), inflammatory reactions, Kaposi Sarcoma, Kostmann Disease, lupus erythematosus, macrophagic myo fasciitis, juvenile idiopathic arthritis, granulomatous arthritis, malignant melanoma, multiple myeloma, rheumatoid arthritis, Sjogren syndrome, Spinocerebellar Ataxia 1, Spinocerebellar Ataxia 7, Whipple's Disease or Wilson's Disease.
  • ALS amyotrophic lateral
  • the resent invention is directed to compounds of Formula (I) and (II)
  • X is S or O
  • Het is selected from pyridinyl and pyrimidinyl, each of which can be optionally substituted with halo, cyano, Ci-3alkyl, Ci-3alkyloxy, -CF 3 , and -OCF3;
  • Ar is phenyl optionally substituted with halo, cyano, Ci-3alkyl, Ci-3alkyloxy, -CF3,
  • R a is selected from H, or Ci-3alkyl
  • R 3 is selected from the group consisting of C3- 6 cycloalkyl; Het 1 ; Ar 1 ; tetrahydro-2H- pyranyl; C3- 6 cycloalkyloxy; tetrahydro-2H-pyranyloxy; Het'-oxy-; and Ar'-oxy-;
  • Ar 1 is phenyl optionally substituted with halo, cyano, Ci-3alkyl, Ci-3alkyloxy, cyano- Ci_ 3 alkyloxy -CF 3 , or -OCF3;
  • Het 1 is selected from the group consisting of pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thienyl, pyrazolyl, isoxazolyl, lH-imidazolyl, thiazolyl, oxazolyl, 1H- indolyl, and lH-indazolyl; each of which is optionally substituted with 1 or 2 substituents each independently selected from the group consisting of halo, cyano, Ci_3alkyl, Ci-3alkyloxy, -CF3, and -OCF3;
  • R x is hydrogen or Ci-3alkyl
  • R y is Ci_3alkyl or phenyl optionally substituted 1 , 2, or 3 substituents each
  • heterocyclyl is selected from the group consisting of piperidinyl, morpholinyl, 3,4-dihydro-2H-pyranyl; and tetrahydro-2H-pyranyl, each of which being optionally substituted with 1 , 2 or 3 substituents each independently selected from the group consisting of Ci-3alkyl, C3- 6 cycloalkyl and oxo;
  • heteroaryl is selected from the group consisting of pyridyl, 2-oxo-l,2-dihydropyridinyl, 6-oxo-l,6-dihydropyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrazolyl, isoxazolyl, oxazolyl, thiophenyl, indolyl, indazolyl, 1-benzothienyl, 1-benzofuranyl, isoquinolinyl, 5,6,7,8-tetrahydroquinolinyl, 3,4-dihydro-2H-chromenyl and 3,4-dihydro-2H- pyrido[3,2-b][l,4]oxazinyl, each of which is optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, Ci_3alkyl, mono-haloCi_3alky
  • R lc is hydrogen or Ci-3alkyl
  • R ld is Ci-3alkyl
  • NR lc R ld form together 1-pyrrolidinyl, 1-piperidinyl, 4-piperazinyl, 4-morpholinyl or lH-imidazolyl, each of which is optionally substituted with Ci-3alkyl;
  • R 2 is hydrogen or Ci-3alkyl
  • Illustrative of the invention is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and any of the compounds described above.
  • An illustration of the invention is a pharmaceutical composition made by mixing any of the compounds described above and a pharmaceutically acceptable carrier.
  • Illustrating the invention is a process for making a pharmaceutical composition comprising mixing any of the compounds described above and a pharmaceutically acceptable carrier.
  • Exemplifying the invention are methods of treating a disorder mediated by the beta-secretase enzyme, comprising administering to a subject in need thereof a therapeutically effective amount of any of the compounds or pharmaceutical compositions described above.
  • An example of the invention is a method of treating a disorder selected from the group consisting of Alzheimer's disease, mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease, dementia associated with beta-amyloid, and age-related macular degeneration, preferably Alzheimer's disease, type 2 diabetes and other metabolic disorders, comprising administering to a subject in need thereof, a therapeutically effective amount of any of the compounds or pharmaceutical compositions described above.
  • Another example of the invention is any of the compounds described above for use in treating: (a) Alzheimer's Disease, (b) mild cognitive impairment, (c) senility, (d) dementia, (e) dementia with Lewy bodies, (f) Down's syndrome, (g) dementia associated with stroke, (h) dementia associated with Parkinson's disease, (i) dementia associated with beta-amyloid or j) age-related macular degeneration, (k) type 2 diabetes and (1) other metabolic disorders in a subject in need thereof.
  • the present invention is directed to compounds of formula (I) as defined hereinbefore, and pharmaceutically acceptable addition salts and solvates thereof.
  • the compounds of formula (I) are inhibitors of the beta-secretase enzyme (also known as beta-site cleaving enzyme, BACE, BACEl , Asp2 or memapsin 2, or BACE2), and may be useful in the treatment of Alzheimer's disease, mild cognitive impairment, senility, dementia, dementia associated with stroke, dementia with Lewy bodies, Down's syndrome, dementia associated with Parkinson's disease, dementia associated with beta-amyloid, and age-related macular degeneration, preferably Alzheimer's disease, mild cognitive impairment or dementia, more preferably Alzheimer's disease, type 2 diabetes and other metabolic disorders.
  • the beta-secretase enzyme also known as beta-site cleaving enzyme, BACE, BACEl , Asp2 or memapsin 2, or BACE2
  • the invention relates to compounds of Formula (I) and (III) as described herein, wherein
  • X is S or O
  • R is phenyl optionally substituted with 1 , 2 or 3 substituents each independently selected from the group consisting of halo; hydroxyl; Ci_3alkyl; cyano; nitro; Het; Ar; (Ci-3alkyloxy)Ci-3alkyl-NH-Ci-3alkyl-; Ci- 6 alkyloxy optionally substituted with cyano, or Ci-3alkyloxy; C 2 _6alkynyloxy; tetrahydro-2H-pyranyloxy; Ar-oxy-; Het-oxy-;
  • Het is selected from pyridinyl and pyrimidinyl, each of which can be optionally substituted with cyano;
  • Ar is phenyl; R a is selected from H, or Ci-3alkyl; and
  • R 3 is selected from the group consisting of C3- 6 cycloalkyl; Het 1 ; Ar 1 ; tetrahydro-2H- pyranyl; C3- 6 cycloalkyloxy; tetrahydro-2H-pyranyloxy; He ⁇ -oxy-; and Ar ⁇ oxy-;
  • Ar 1 is phenyl optionally substituted with halo, cyano, Ci-3alkyl, and Ci-3alkyloxy;
  • Het 1 is selected from the group consisting of pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thienyl, pyrazolyl, isoxazolyl, lH-imidazolyl, thiazolyl, oxazolyl, 1H- indolyl, and lH-indazolyl; each of which is optionally substituted with 1 or 2 substituents each independently selected from the group consisting of halo, cyano, and Ci-3alkyl;
  • heterocyclyl is 3,4-dihydro-2H-pyranyl
  • Ci-3alkyloxy wherein R la is hydrogen or Ci-3alkyl and R lb is Ci-3alkyl, or NR la R lb form together a 4-morpholinyl;
  • heteroaryl is selected from the group consisting of pyridyl, 2-oxo-l,2-dihydropyridinyl, 6-oxo-l,6-dihydropyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrazolyl, isoxazolyl, oxazolyl, thiophenyl, indolyl, indazolyl, 1-benzothienyl, 1-benzofuranyl, isoquinolinyl, 5,6,7,8-tetrahydroquinolinyl, 3,4-dihydro-2H-chromenyl and 3,4-dihydro-2H- pyrido[3,2-b][l,4]oxazinyl, each of which is optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, Ci-3alkyl, mono-haloCi-3alkyl,
  • R lc is hydrogen or Ci-3alkyl
  • R ld is Ci-3alkyl
  • NR lc R ld form together 1-pyrrolidinyl, 1-piperidinyl, 4-piperazinyl, 4-morpholinyl or lH-imidazolyl, each of which is optionally substituted with Ci-3alkyl
  • R 2 is hydrogen or Ci-3alkyl.
  • the invention relates to compounds of Formula (I) and (II) as described herein, wherein
  • X is S or O
  • R is phenyl optionally substituted with 1 , 2 or 3 substituents each independently selected from the group consisting of halo; hydroxyl; nitro; Het; Ci_6alkyloxy optionally substituted with cyano, or Ci- 3 alkyloxy; C 2 _6alkynyloxy; tetrahydro-2H- pyranyloxy; Het-oxy-; -NR a R b ; a divalent -NH-CH 2 CH 2 -0- substituent optionally substituted with 1 or 2 substituents each independently selected from halo and oxo; and R 3 -Ci-6alkyloxy-; wherein
  • Het is selected from pyridinyl and pyrimidinyl, each of which can be optionally substituted with cyano;
  • Ar is phenyl
  • R a is H
  • R 3 is selected from the group consisting of C 3 - 6 cycloalkyl; Het 1 ; Ar 1 ; tetrahydro-2H- pyranyl; C 3 - 6 cycloalkyloxy; tetrahydro-2H-pyranyloxy; He ⁇ -oxy-; and Ar ⁇ oxy-;
  • Ar 1 is phenyl optionally substituted with halo, cyano, Ci_ 3 alkyl, and Ci_ 3 alkyloxy;
  • Het 1 is selected from the group consisting of pyridyl, pyrimidinyl, isoxazolyl, 1H- imidazolyl, thiazolyl, and lH-indazolyl; each of which is optionally substituted with 1 or 2 substituents each independently selected from Ci_ 3 alkyl;
  • heterocyclyl is 3,4-dihydro-2H-pyranyl
  • homoaryl is phenyl optionally substituted with 1 , 2 or 3 substituents each independently selected from the group consisting of halo, hydroxyl, cyano, Ci_ 3 alkyl, mono-halo-
  • heteroaryl is selected from the group consisting of pyridyl, 2-oxo-l,2-dihydropyridinyl, 6-oxo-l,6-dihydropyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrazolyl, isoxazolyl, oxazolyl, thiophenyl, indolyl, indazolyl, 1-benzothienyl, 1-benzofuranyl, isoquinolinyl, 5,6,7,8-tetrahydroquinolinyl, 3,4-dihydro-2H-chromenyl and 3,4-dihydro-2H- pyrido[3,2-b][l,4]oxazinyl, each of which is optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, Ci_3alkyl, mono-haloCi-3alkyl
  • R lc is hydrogen or Ci-3alkyl
  • R ld is Ci-3alkyl
  • NR lc R ld form together 1-pyrrolidinyl, 4-piperazinyl, or lH-imidazolyl, each of which is optionally substituted with Ci-3alkyl
  • R 2 is hydrogen or Ci-3alkyl.
  • the invention relates to compounds of Formula (I) and (II) as described herein, wherein
  • R is phenyl optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo; and Het; wherein
  • Het is selected from pyridinyl and pyrimidinyl, each of which can be optionally substituted with cyano.
  • the invention relates to compounds of Formula (I) and (II) as described herein, wherein
  • X is S or O
  • R is phenyl optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo; Ci- 6 alkyloxy optionally substituted with cyano, or Ci-3alkyloxy; C2- 6 alkynyloxy; tetrahydro-2H-pyranyloxy; and R 3 - Ci- 6 alkyloxy-; wherein
  • R 3 is selected from the group consisting of C3- 6 cycloalkyl; Ar 1 ; tetrahydro-2H-pyranyl; C3- 6 cycloalkyloxy; tetrahydro-2H-pyranyloxy; Het'-oxy-; and Ar'-oxy-; wherein
  • Ar 1 is phenyl optionally substituted with halo, cyano, Ci-3alkyl, and Ci-3alkyloxy; Het 1 is selected from the group consisting of pyridyl, pyrimidinyl, isoxazolyl, 1H- imidazolyl, thiazolyl, and lH-indazolyl; each of which is optionally substituted with 1 or 2 substituents each independently selected from Ci_3alkyl;
  • R 1 is selected from the group consisting of hydrogen; halo; homoaryl; and heteroaryl; wherein
  • homoaryl is phenyl optionally substituted with 1 or 2 or 3 substituents each
  • heteroaryl is selected from the group consisting of pyridyl and isoxazolyl, each of which is optionally substituted with 1 or 2 substituents each independently selected from the group consisting of halo, Ci-3alkyl and Ci-3alkyloxy; and
  • R 2 is hydrogen or Ci-3alkyl.
  • the invention relates to compounds of Formula (I) and (II) as described herein, wherein
  • X is S or O
  • R 1 is homoaryl or heteroaryl
  • homoaryl is phenyl optionally substituted with 1 or 2 substituents each independently selected from the group consisting of halo, cyano, and Ci-3alkyl;
  • heteroaryl is selected from the group consisting of pyridyl, and isoxazolyl, each of which is optionally substituted with 1 or 2 substituents each independently selected from the group consisting of halo, cyano, and Ci-3alkyl; and
  • R 2 is hydrogen or Ci-3alkyl.
  • the invention relates in particular to compounds wherein carbon centres C 4a and Cioa in the tricyclic scaffold are of cis configuration (i.e. H and R are projected towards the same side out of the plane of the scaffold)
  • the invention relates to compounds of Formula ( ⁇ ) and ( ⁇ ") and compounds of Formula ( ⁇ ) and (II") as represented below, wherein the tricyclic core is in the plane of the drawing and H and R are projected above the plane of the drawing (with the bond shown with a bold wedge ) in ( ⁇ ) and (IF) or wherein the tricyclic core is in the plane of the drawing and H and R are projected below the plane of the
  • Halo shall denote fluoro, chloro and bromo
  • Ci-3alkyl and “Ci-6alkyl” shall denote a straight or branched saturated alkyl group having 1, 2 or 3 carbon atoms or 1, 2, 3, 4, 5, or 6 carbon atoms, respectively e.g. methyl, ethyl, 1-propyl, 2-propyl, etc.
  • subject refers to an animal, preferably a mammal, most preferably a human, who is or has been the object of treatment, observation or experiment.
  • terapéuticaally effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.
  • the invention includes all stereoisomers of the compound of Formula (I) either as a pure stereoisomer or as a mixture of two or more stereoisomers.
  • Enantiomers are stereoisomers that are non-superimposable mirror images of each other.
  • a 1 : 1 mixture of a pair of enantiomers is a racemate or racemic mixture.
  • Diastereomers or diastereoisomers are stereoisomers that are not enantiomers, i.e. they are not related as mirror images. If a compound contains a double bond, the substituents may be in the E or the Z configuration. If a compound contains a disubstituted cycloalkyl group, the substituents may be in the cis or trans configuration. Therefore, the invention includes enantiomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof.
  • the absolute configuration is specified according to the Cahn-Ingold-Prelog system.
  • the configuration at an asymmetric atom is specified by either R or S.
  • Resolved compounds whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light.
  • stereoisomer When a specific stereoisomer is identified, this means that said stereoisomer is substantially free, i.e. associated with less than 50%, preferably less than 20%, more preferably less than 10%, even more preferably less than 5%, in particular less than 2% and most preferably less than 1%, of the other isomers.
  • a compound of formula (I) is for instance specified as (R), this means that the compound is
  • addition salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable addition salts". Other salts may, however, be useful in the preparation of compounds according to this invention or of their pharmaceutically acceptable addition salts.
  • Suitable pharmaceutically acceptable addition salts of the compounds include acid addition salts which may, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
  • suitable pharmaceutically acceptable addition salts thereof may include alkali metal salts, e.g., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts.
  • acids which may be used in the preparation of pharmaceutically acceptable addition salts include, but are not limited to, the following: acetic acid, 2,2- dichloroactic acid, acylated amino acids, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 4- acetamidobenzoic acid, (+)-camphoric acid, camphorsulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, ethane- 1 ,2-disulfonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic acid, D-glucoronic acid, L-glutamic acid, beta- oxo-glutaric acid, glycolic acid, hippuric
  • Representative bases which may be used in the preparation of pharmaceutically acceptable addition salts include, but are not limited to, the following: ammonia, L- arginine, benethamine, benzathine, calcium hydroxide, choline, dimethylethanolamine, diethanolamine, diethylamine, 2-(diethylamino)-ethanol, ethanolamine, ethylene- diamine, N-methyl-glucamine, hydrabamine, lH-imidazole, L-lysine, magnesium hydroxide, 4-(2-hydroxyethyl)-morpholine, piperazine, potassium hydroxide, l-(2-hydroxyethyl)-pyrrolidine, secondary amine, sodium hydroxide, triethanolamine, tromethamine and zinc hydroxide.
  • a particular salt is the trifluoroacetic acid addition salt.
  • Final compounds according to Formula (I) and (II) can be prepared by deprotecting intermediate compounds of Formula (III) and (IV) wherein Q represents a base labile (e.g. an acyl) or acid labile (e.g. a trityl) protecting group (Reaction Scheme 1). Such reactions can be performed under art-known reaction conditions.
  • Q represents a base labile (e.g. an acyl) or acid labile (e.g. a trityl) protecting group
  • final compounds according to Formula (I) can be obtained by functional group interconversion of R 1 by art-known methods, such as, for example, exchanging a bromine for a heterocycle by using standard cross coupling reactions, such as, for example, the Suzuki reaction.
  • Intermediates of Formula (III) or (IV) wherein R la represents Ci_3alkyl, (C3-6cycloalkyl)Ci-3alkyl, homoaryl, heteroaryl or heterocyclyl, herein referred to as intermediates of Formula (Ill-a) and (IV-a) respectively, can be prepared by a Suzuki- Miyaura cross coupling reaction of the corresponding intermediate of Formula (Ill-b) or (IV-b) wherein R lb represents halo, preferably bromo, with an intermediate of Formula (V) wherein R la is as defined hereinbefore and R a and R b may be hydrogen or Ci-4alkyl, or may be taken together to form a bivalent radical of formula CH2CH2, CH2CH2CH2, or C(CH3)2C(CH3)2 (Reaction Scheme 2).
  • the reaction can be performed in a suitable reaction inert solvent, such as, toluene, or mixtures of inert solvents such as, for example, 1 ,4-dioxane/water in the presence of a suitable base, such as, for example, potassium phosphate tribasic or potassium carbonate, a suitable Pd-complex catalyst such as, for example, palladium (II) acetate, and a suitable ligand, such as, for example, tricyclohexylphosphine, at an elevated temperature in the range of 60 to
  • Intermediates of Formula (IV) wherein R 2 is Ci-3alkyl herein referred to as intermediates of Formula (IV-c) can be prepared by reaction the corresponding intermediates of Formula (III) wherein R 2 is methyl, herein referred to as intermediates of Formula (III-c), with Ci-3alkyl iodide (Reaction Scheme 3).
  • the reaction can be performed under thermal conditions such as, for example, heating the reaction mixture at 100 °C.
  • Reaction Scheme 3 all variables are defined as in Formula (I).
  • Intermediate compounds of Formula (IV) wherein R 2 is hydrogen herein referred to as (IV-d) can be prepared from an intermediate compound of Formula (III- c), following art-known O-demethylation procedures. Said transformation may conveniently be conducted by treatment of intermediate (III-c) with a suitable O- demethylating agent, such as, trimethylchlorosilane, in the presence of a suitable additive such as, sodium iodide, in a suitable inert solvent such as, acetonitrile, under suitable reaction conditions, such as at a convenient temperature, typically 50°C, for a period of time to ensure the completion of the reaction.
  • a suitable O- demethylating agent such as, trimethylchlorosilane
  • carbonylation may conveniently be conducted by stirring an intermediate compound of Formula (Ill-b) under a carbon monoxide atmosphere in the presence of a suitable palladium catalyst, such as, for example, palladium acetate, a suitable ligand, such as, l ,3-bis(diphenylphosphino)propane and a suitable base, such as, potassium acetate in a suitable reaction solvent or mixtures of solvents such as, for example, THF/EtOH.
  • Reaction may be carried out in an autoclave at a suitable pressure such as, for example, 30 bar, at a convenient temperature, typically 120 °C, for a period of time to ensure the completion of the reaction.
  • a suitable palladium catalyst such as, for example, palladium acetate
  • a suitable ligand such as, l ,3-bis(diphenylphosphino)propane
  • a suitable base such as, potassium acetate
  • Reaction may be carried out in an autoclave at
  • intermediate compound of Formula (Ill-d) wherein Ri is hydrogen by art-known bromination procedures.
  • Said bromination may conveniently be conducted by treatment of the corresponding intermediate compounds of Formula (Ill-f) with a brominating agent such as, for example, N-bromosuccinimide in a suitable inert solvent such as, for example, acetonitrile and the like at a suitable temperature such as, for example, room temperature until completion of the reaction, for example 16 hours.
  • a brominating agent such as, for example, N-bromosuccinimide
  • a suitable inert solvent such as, for example, acetonitrile and the like
  • Intermediates compound of Formula (Ill-f) may need to be protected by a protecting group PG such as, for example, tert-butoxycarbonyl group, following art- known procedures.
  • Said reaction can conveniently be conducted by treatment of intermediate compound (Ill-f) with di-tert-butyl dicarbonate, in the presence of a suitable catalyst, such as, 4-(dimethylamino)pyridine (DMAP), in a suitable inert solvent such as, THF, under suitable reaction conditions, such as at a convenient temperature, typically r.t., for a period of time to ensure the completion of the reaction.
  • a suitable catalyst such as, 4-(dimethylamino)pyridine (DMAP)
  • DMAP 4-(dimethylamino)pyridine
  • the protected intermediate (Ill-g) may then be brominated as described above to yield (Ill-h) which than may be deprotected by treatment with a suitable acid, such as for example, trifluoroacetic acid of formic acid in a suitable solvent, or neat, at ambient temperature to yield intermediate (Ill-b).
  • a suitable acid such as for example, trifluoroacetic acid of formic acid in a suitable solvent, or neat
  • Intermediate compounds of Formula (III) can be prepared from an intermediate compound of Formula (VI) following art-known cyclization procedures. Said cyclization may conveniently be conducted by treatment of an intermediate compound of Formula (VI) with a suitable reagent, such as l-chloro-N,N-2- trimethylpropenylamine, in a suitable reaction solvent, such as for example DCM under suitable reaction conditions, such as at a convenient temperature, typically r.t., for a period of time to ensure the completion of the reaction.
  • a suitable reagent such as l-chloro-N,N-2- trimethylpropenylamine
  • a suitable reagent such as, benzyl isothiocyanate
  • a suitable inert solvent such as, for example, DCM
  • Intermediate compounds of Formula (VII) can be prepared from the corresponding intermediate compounds of Formula (VIII) following art-known aziridine ring opening procedures.
  • Said reaction may be carried out by stirring the reactants under a hydrogen atmosphere in the presence of an appropriate catalyst such as, for example, Raney-nickel in a suitable solvent, such as, for example, alkanols, e.g. methanol, ethanol and the like, at a convenient temperature, typically r.t., until completion of the reaction, for example 6 hours.
  • an appropriate catalyst such as, for example, Raney-nickel in a suitable solvent, such as, for example, alkanols, e.g. methanol, ethanol and the like
  • Intermediate compounds of Formula (VIII) can be prepared by reacting the corresponding intermediate compounds of Formula (IX) with an intermediate of Formula (X).
  • the reaction can be performed in a suitable reaction inert solvent, such as, THF under suitable reaction conditions, such as at a suitable temperature, typically in a range between -78 °C and room temperature, for a period of time to ensure the completion of the reaction.
  • An intermediate compound of Formula (X) can be obtained commercially or synthesized according to literature procedures.
  • Intermediate compounds of Formula (IX) can be prepared by reacting the corresponding intermediate compounds of Formula (XI) following art-known cyclization procedures. Said cyclization may be conveniently conducted by treatment of an intermediate compound of Formula (XI) with a suitable acid, such as, for example hydrochloric acid, in a suitable reaction inert solvent, such as, THF under suitable reaction conditions, such as at a suitable temperature, typically 50 °C, for a period of time to ensure the completion of the reaction.
  • a suitable acid such as, for example hydrochloric acid
  • a suitable reaction inert solvent such as, THF
  • suitable reaction conditions such as at a suitable temperature, typically 50 °C
  • Intermediate compounds of Formula (XI) can be prepared by reacting the intermediate compounds of Formula (XII) following art-known coupling procedures. Said transformation may be conveniently conducted by conversion of an intermediate compound of Formula (XII) to the corresponding cyanocuprate reagent in the presence of a suitable metalation reagent, such as, isopropylmagnesium chloride lithium chloride complex, and a suitable organocuprate precursor, such as, for example, copper(I) cyanide di(lithium chloride) complex solution, followed by addition of a suitable halide, such as allyl bromide.
  • a suitable metalation reagent such as, isopropylmagnesium chloride lithium chloride complex
  • a suitable organocuprate precursor such as, for example, copper(I) cyanide di(lithium chloride) complex solution
  • a suitable halide such as allyl bromide.
  • Reaction may be performed in a suitable inert solvent, such as, for example, THF and the like solvents, at a convenient temperature, typically -70 °C-r.t. for a period of time to ensure the completion of the reaction.
  • a suitable inert solvent such as, for example, THF and the like solvents
  • Said reaction may conveniently be conducted by treatment of the intermediate compound of Formula (XIII) with a suitable phosphonium salt, such as, for example, methoxymethyl triphenylphosphonium chloride, in the presence of a suitable base such as, for example, potassium bis(trimethylsilyl)amide, in a suitable reaction-inert solvent, such as, for example, toluene, at convenient temperature, typically -10 °C-r.t., for a period of time to ensure the completion of the reaction.
  • a suitable phosphonium salt such as, for example, methoxymethyl triphenylphosphonium chloride
  • a suitable base such as, for example, potassium bis(trimethylsilyl)amide
  • a suitable reaction-inert solvent such as, for example, toluene
  • intermediate compounds of Formula (IX) can undergo addition of an organometallic species of Formula (XIV), where R is any radical which can be converted into R by using procedures known to the person skilled in the art, such as, for example, cross coupling reactions, alkylation reactions and deprotection reactions.
  • R any radical which can be converted into R by using procedures known to the person skilled in the art, such as, for example, cross coupling reactions, alkylation reactions and deprotection reactions.
  • Intermediate compounds (VHI-a) can be carried on in the synthesis using the same synthetic pathway described in the examples before. The person skilled in the art will be able to judge at which point of the synthetic sequence the conversion of R to R is appropriate to perform.
  • the flow synthesis system utilized the Vapourtec® R4 reactors and R2 pump modules with integrated valves and reagent loops controlled by FlowCommanderTM software. Up to four reactors, pumps and valves were used depending on the complexity of the chemistry.
  • the output from the final reactor flowed into a HPLC injection valve enabling an aliquot of product to be injected onto the purification system. Loss of material due to dispersion in the synthesis system was minimized in several ways. Firstly small bore tubing was used throughout the system as this minimised dispersion. Secondly, the reagent loop sizes were selected to ensure a steady state concentration of reactants and product was achieved in the reactor. Finally, the injection to HPLC was timed to ensure that an aliquot was taken at the point of maximum product
  • the reactions are typically performed under appropriate reaction conditions typically at 150°C for twenty minutes with a two-fold excess of coupling agent with respect to intermediate (XIV), and three equivalents of base.
  • the reaction mixture is passed through a silica cartridge to remove palladium catalyst before automatic LCMS purification.
  • the compounds of the present invention and the pharmaceutically acceptable compositions thereof inhibit BACE and therefore may be useful in the treatment or prevention of Alzheimer's Disease (AD), mild cognitive impairment (MCI), senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, Down's syndrome, dementia associated with Parkinson's disease, dementia of the Alzheimer's type, vascular dementia, dementia due to HIV disease, dementia due to head trauma, dementia due to Huntington's disease, dementia due to Pick's disease, dementia due to Creutzfeldt- Jakob disease, frontotemporal dementia, dementia pugilistica, dementia associated with beta-amyloid and age related macular
  • treatment is intended to refer to all processes, wherein there may be a slowing, interrupting, arresting or stopping of the progression of a disease or an alleviation of symptoms, but does not necessarily indicate a total elimination of all symptoms.
  • the invention also relates to a compound according to the general Formula (I), a stereoisomeric form thereof or a pharmaceutically acceptable acid or base addition salt thereof, for use in the treatment or prevention of diseases or conditions selected from the group consisting of AD, MCI, senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, Down's syndrome, dementia associated with Parkinson's disease, dementia of the Alzheimer's type, dementia associated with beta-amyloid and age related macular degeneration, type 2 diabetes and other metabolic disorders.
  • diseases or conditions selected from the group consisting of AD, MCI, senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, Down's syndrome, dementia associated with Parkinson's disease, dementia of the Alzheimer's type, dementia associated with beta-amyloid and age related macular degeneration, type 2 diabetes and other metabolic disorders.
  • the invention also relates to a compound according to the general Formula (I), a stereoisomeric form thereof or a pharmaceutically acceptable acid or base addition salt thereof, for use in the treatment, prevention, amelioration, control or reduction of the risk of diseases or conditions selected from the group consisting of AD, MCI, senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi- infarct dementia, Down's syndrome, dementia associated with Parkinson's disease, dementia of the Alzheimer's type, dementia associated with beta-amyloid and age related macular degeneration, type 2 diabetes and other metabolic disorders.
  • AD Alzheimer's type
  • dementia associated with beta-amyloid and age related macular degeneration type 2 diabetes and other metabolic disorders.
  • treatment does not necessarily indicate a total elimination of all symptoms, but may also refer to symptomatic treatment in any of the disorders mentioned above.
  • a method of treating subjects such as warm-blooded animals, including humans, suffering from or a method of preventing subjects such as warm-blooded animals, including humans, suffering from any one of the diseases mentioned hereinbefore.
  • Said methods comprise the administration, i.e. the systemic or topical administration, preferably oral administration, of a therapeutically effective amount of a compound of Formula (I), a stereoisomeric form thereof, a pharmaceutically acceptable addition salt or solvate thereof, to a subject such as a warm-blooded animal, including a human.
  • the invention also relates to a method for the prevention and/or treatment of any of the diseases mentioned hereinbefore comprising administering a therapeutically effective amount of a compound according to the invention to a subject in need thereof.
  • the invention also relates to a method for modulating beta-site amyloid cleaving enzyme activity, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound according to the invention and as defined in the claims or a pharmaceutical composition according to the invention and as defined in the claims.
  • a method of treatment may also include administering the active ingredient on a regimen of between one and four intakes per day.
  • the compounds according to the invention are preferably formulated prior to
  • suitable pharmaceutical formulations are prepared by known procedures using well known and readily available ingredients.
  • the compounds of the present invention may be administered alone or in combination with one or more additional therapeutic agents.
  • Combination therapy includes administration of a single pharmaceutical dosage formulation which contains a compound of Formula (I) and one or more additional therapeutic agents, as well as administration of the compound of Formula (I) and each additional therapeutic agent in its own separate pharmaceutical dosage formulation.
  • a compound of Formula (I) and a therapeutic agent may be administered to the patient together in a single oral dosage composition such as a tablet or capsule, or each agent may be administered in separate oral dosage formulations.
  • DSM-5TM Diagnostic & Statistical Manual of Mental Disorders
  • NCDs neurocognitive disorders
  • TBI traumatic brain injury
  • Lewy body disease due to Lewy body disease
  • Parkinson's disease due to Parkinson's disease or to vascular NCD (such as vascular NCD present with multiple infarctions).
  • vascular NCD such as vascular NCD present with multiple infarctions.
  • the present invention also provides compositions for preventing or treating diseases in which inhibition of beta-secretase is beneficial, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with AD
  • AD Alzheimer's disease
  • compositions comprising a therapeutically effective amount of a compound according to formula (I) and a pharmaceutically acceptable carrier or diluent.
  • the present invention further provides a pharmaceutical composition comprising a compound according to the present invention, together with a pharmaceutically acceptable carrier or diluent.
  • a pharmaceutically acceptable carrier or diluent must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.
  • compositions of this invention may be prepared by any methods well known in the art of pharmacy.
  • a therapeutically effective amount of the particular compound, in base form or addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which may take a wide variety of forms depending on the form of preparation desired for administration.
  • a pharmaceutically acceptable carrier which may take a wide variety of forms depending on the form of preparation desired for administration.
  • These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for systemic administration such as oral, percutaneous or parenteral administration; or topical administration such as via inhalation, a nose spray, eye drops or via a cream, gel, shampoo or the like.
  • any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed.
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
  • Injectable solutions may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
  • the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause any significant deleterious effects on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions.
  • transdermal patch e.g., as a transdermal patch, as a spot-on or as an ointment.
  • Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
  • the exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention.
  • the pharmaceutical composition will comprise from 0.05 to 99% by weight, preferably from 0.1 to 70%> by weight, more preferably from 0.1 to 50% by weight of the active ingredient, and, from 1 to 99.95% by weight, preferably from 30 to 99.9% by weight, more preferably from 50 to 99.9% by weight of a pharmaceutically acceptable carrier, all percentages being based on the total weight of the composition.
  • the present compounds can be used for systemic administration such as oral, percutaneous or parenteral administration; or topical administration such as via inhalation, a nose spray, eye drops or via a cream, gel, shampoo or the like.
  • the compounds are preferably orally administered.
  • the exact dosage and frequency of administration depends on the particular compound according to formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art.
  • said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention.
  • suitable unit doses for the compounds of the present invention can, for example, preferably contain between 0.1 mg to about 1000 mg of the active compound.
  • a preferred unit dose is between 1 mg to about 500 mg.
  • a more preferred unit dose is between 1 mg to about 300 mg.
  • Even more preferred unit dose is between 1 mg to about 100 mg.
  • Such unit doses can be administered more than once a day, for example, 2, 3, 4, 5 or 6 times a day, but preferably 1 or 2 times per day, so that the total dosage for a 70 kg adult is in the range of 0.001 to about 15 mg per kg weight of subject per administration.
  • a preferred dosage is 0.01 to about 1.5 mg per kg weight of subject per administration, and such therapy can extend for a number of weeks or months, and in some cases, years.
  • the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the individual being treated; the time and route of administration; the rate of excretion; other drugs that have previously been administered; and the severity of the particular disease undergoing therapy, as is well understood by those of skill in the area.
  • a typical dosage can be one 1 mg to about 100 mg tablet or 1 mg to about 300 mg taken once a day, or, multiple times per day, or one time-release capsule or tablet taken once a day and containing a proportionally higher content of active ingredient.
  • the time-release effect can be obtained by capsule materials that dissolve at different pH values, by capsules that release slowly by osmotic pressure, or by any other known means of controlled release.
  • compositions, methods and kits provided above, one of skill in the art will understand that preferred compounds for use in each are those compounds that are noted as preferred above. Still further preferred compounds for the compositions, methods and kits are those compounds provided in the non-limiting Examples below.
  • HSS High Strength silica
  • Q-Tof Quadrupole Time- of- flight mass spectrometers
  • CLND ChemiLuminescent Nitrogen Detector
  • ELSD Evaporative Light Scanning Detector
  • the stereoconfiguration corresponds with C 4a (R),C 10 a(S) and the compound is a single diastereoisomer and enantiopure;
  • the r.m. was diluted with sat. NaHC0 3 sol. (0.1 L) and the layers were separated.
  • the organic layer was dried over MgSC ⁇ , filtered and transferred to a 1 L 4 neck flask, equipped with a mechanical stirrer and cooled to 0 °C (internal temperature).
  • sodium hypochlorite 210 mL, 470 mmol
  • the r.m. was allowed to come to r.t. and stirring was continued at r.t. overnight.
  • the layers were separated and the aq. layer was extracted with DCM (0.2 L).
  • the combined organic layers were dried over MgSC ⁇ , filtered and concentrated in vacuo to give a solid which was recrystallized from DIPE (0.1 L) to afford intermediate 4 (8.64 g, 44%).
  • Intermediate 10 was prepared following a synthetic procedure similar to the one reported for the synthesis of intermediate 6. Starting from intermediate 9 (2.8 g, 9.32 mmol) intermediate 10 was obtained and used as such in the next step (2.8 g, quantitative, cis/trans 96/4).
  • Intermediate 11 was prepared following a synthetic procedure similar to the one reported for the synthesis of intermediate 7. Starting from intermediate 10 (1.6 g, 5.29 mmol) intermediate 11 was obtained as a white foam (2.22 g, 90%, cis).
  • Intermediate 12 was prepared following a synthetic procedure similar to the one reported for the synthesis of intermediate 8. Starting from intermediate 11 (2.22 g, 4.77 mmol) intermediate 12 was obtained as a white solid (1.4 g, 66%, cis).
  • a microwave tube was charged with intermediate 15 (150 mg, 0.29 mmol), cyclopropylboronic acid (35 mg, 0.41 mmol), tricyclohexylphosphine (10 mg, 0.036 mmol), potassium phosphate tribasic (200 mg, 0.94 mmol), palladium (II) acetate (5 mg, 0.022 mmol), toluene (5 mL) and water (0.1 mL).
  • the r.m. was purged with nitrogen under vigorously stirring for 5 min, then the tube was capped and heated for 3 h at 120 °C in a DrySyn metal heating block. The r.m.
  • intermediate 26b was obtained starting from intermediate 23b.
  • intermediate 27 (150 mg, 0.226 mmol), zinc dust (5 mg, 0.076 mmol) and zinc cyanide (108 mg, 0.9 mmol) were added.
  • the tube was capped and heated at 120 °C for 12 h. The r.m. was allowed to cool down, poured onto ice water (30 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layers were treated with water (2 x 5 mL), dried over MgSC ⁇ , filtered and concentrated in vacuo to give a brown solid. This solid was purified by column chromatography (silica, MeOH/DCM 0/100 to 1/99) to afford intermediate 28 as a white solid (0.159 g, quantitative, cis), which was used as such in the next step.
  • Tris(dibenzylideneacetone)dipalladium(0) (519.4 mg, 0.57 mmol) and 1,1 '- bis(diphenylphosphino)ferrocene (649.7 mg, 1.17 mmol) were mixed in DMA (106.7 mL) in a mw vial and this mixture was degassed using nitrogen for 10 min.
  • intermediate 32b was prepared starting from intermediate 26b (35% over three steps).
  • Intermediate 33 was prepared following a synthetic procedure similar to the one reported for the synthesis of intermediate 31. Starting from commercially available l-(2-tetrahydropyranyl)-lH-pyrazole-5-boronic acid pinacol ester (147 mg, 0.53 mmol) and intermediate 29 (300 mg, 0.44 mmol) intermediate 33 was obtained (215 mg, 65%, cis).
  • Tetrabutylammonium fluoride (1 M in THF, 2.42 mL, 2.42 mmol) was added dropwise to a sol. of intermediate 35 (1 g, 1.731 mmol) in THF (19.7 mL).
  • the r.m. was strirred at r.t. for 40 min, then it was diluted with 100 mL of DCM, basified with NaHC0 3 sat. sol. mantaining the temperature below 5°Cammonia in MeOH and extracted with DCM.
  • the organic layer was separated, dried with MgS0 4 , filtered and the solvent was evaporated in vacuo.
  • the residue was purified by flash chromatography (silica, MeOH/DCM 0/100 to 1/99). The desired fractions were collected and the solvent evaporated to afford intermediate 36 (790 mg, 99%, cis).
  • Intermediate 39a was prepared following a synthetic procedure similar to the one reported for the synthesis of intermediate 15 (from intermediate 12). Starting from intermediate 35 (three batches of 2.41 g, 1 g and 5.15 g each with reaction times ranging from 1 to 4 h, were combined for purification), intermediate 39 was obtained, which was then separated by preparative SFC (Stationary phase: Kromasil (R,R) Whelk-0 1 (25 x 250 mm), Mobile phase: C0 2 , iPrOH with 0.4% iPrNH 2 ) to afford desired intermediate 39a (942 mg, 16%>) and intermediate 39b (914 mg, 16%>).
  • SFC Sta synthetic procedure similar to the one reported for the synthesis of intermediate 15 (from intermediate 12).
  • intermediate 39 was obtained, which was then separated by preparative SFC (Stationary phase: Kromasil (R,R) Whelk-0 1 (25 x 250 mm), Mobile phase: C0 2 , iPrOH with 0.4% iPrNH 2 )
  • Intermediate 42 was prepared following a synthetic procedure similar to the one reported for the synthesis of intermediate 31a, starting from intermediate 29a and 5- methoxypyridine-3-boronic acid (77 mg, 99% yield).
  • Intermediate 43 was prepared following a synthetic procedure similar to the one reported for the synthesis of intermediate 31a, starting from intermediate 29a and 5- methylpyridine-3-boronic acid (100 mg, 38% LC-MS purity).
  • Intermediate 44 was prepared following a synthetic procedure similar to the one reported for the synthesis of intermediate 31a, starting from intermediate 29a and 4- methoxy-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (280 mg, 37% LC- MS purity).
  • intermediate 45 (cis) was obtained starting from intermediate 35 (40% over two steps, cis).
  • Zinc cyanide 14 mg, 0.118 mmol was added to a stirred mixture of intermediate 40 (140 mg, 0.235 mmol) and Pd(PPh 3 ) 4 (14 mg, 0.012 mmol) in DMF (1 mL) under nitrogen.
  • the mixture was heated at 120 °C for 20 min under microwave irradiation, then it mixed with another batch of material from a r.m. resulting from use of 54 mg of intermediate 40, the resulting mixture was diluted with EtO Ac and the solid was filtered off through a celite pad.
  • the filtrate was basified with sat. aq. Na 2 C0 3 .
  • the organic layer was separated, dried over Na 2 S0 4 , filtered and the solvent was evaporated.
  • the residue was purified by flash column chromatography (silica,
  • intermediate 50 (cis) was obtained starting from intermediate 49 (42% over three steps, cis).
  • intermediate 57 was prepared starting from intermediate 39 (racemic) (200 mg, 79%, cis).
  • intermediate 54 was prepared starting from intermediate 53 (15%, cis).
  • intermediate 55 was obtained starting from intermediate 40 (cis) (two batches of 420 mg and 100 mg were combined prior to purification by column chromatography) and 5-cyano-3-pyridinyl boronic acid (320 mg, 67%).
  • Lithium aluminium hydride (2 M in THF, 0.21 mL, 0.42 mmol) was added dropwise to a solution of intermediate 59 (100 mg, 0.21 mmol) in THF (13.3 mL) under nitrogen cooled at -20 °C.
  • the solution was stirred at r.t. for 16 h, then cooled with an ice bath and quenched with 5% Rochelle salt solution.
  • the mixture was extracted with DCM, the organic layer collected, dried over MgS0 4 , filtered and concentrated in vacuo. The residue was purified by flash column chromatography (silica, 7 M ammonia in
  • Boc anhydride 150 ⁇ , 0.70 mmol was added at rt to a solution of compound 30 (80 mg, 023 mmol) and DIPEA (200 ⁇ , 1.16 mmol) in DCM (4 mL). The r.m. was stirred at r.t. overnight. Sat. NaHC0 3 sol. was added and the organic layer was separated, dried over MgSC ⁇ and filtered. The residue was purified by column chromatography (silica; flash purification system, gradient EtO Ac/heptane from 0/100 to 90/10 step 20/80, 40/60, 60/40 and 80/20 12g 20 min). The product fractions were collected and the solvent was evaporated to yield intermediate 62 (80 mg, 78%) as a colourless oil.
  • intermediate 39 (100 mg, 0.152 mmol) in EtOH (1.4 mL), to afford a suspension which turned into a solution after stirring at r.t. for 16 h. The r.m. was then evaporated and the crude purified by flash column chromatography (silica, 7 M ammonia in MeOH/DCM 0/100 to 1/99 to afford intermediate 69 (64 mg, 76%, cis) as a white solid.
  • Triethylamine (14 ⁇ , 0.1 mmol) and triphenylmethyl chloride (37 mg, 0.133 mmol) were added to a solution of compound 18 (39 mg, 0.9 mmol) in dry MeCN (5 mL). The r.m. was heated to 80 °C for 3 h. Additional triphenylmethyl chloride (0.4 eq) was added and the r.m. heated to 80 °C for 1 h, then the solvent was evaporated, the organic residue dissolved in EtO Ac and the r.m. basified with K2CO3. The organic layer was washed with brine (3 x), dried over MgS0 4 , filtered and concentrated in vacuo.
  • the crude was purified by flash chromatography on silica gel (gradient: EtO Ac/heptane 0/100 to 10/90).
  • the product was isolated contaminated with byproducts from the previous step and various amounts of heptane and EtO Ac (155 mg).
  • Step 1 To stirred mixture of intermediate 14 (0.15 g, 0.24 mol) in DCM (5 mL) was added TFA (1 mL, 13 mmol). After 10 min the r.m. was diluted with DCM (20 mL) and sat. aq. NaHC0 3 sol. until basic pH and the layers were separated. The organic layer was dried over MgS04, filtered and concentrated in vacuo to give an oil.
  • Step 2 This oil was dissolved in MeOH (10 mL) and treated with DBU (0.36 mL, 2.4 mmol). The r.m. was heated at 65 °C for 16 h, then the r.m. was concentrated in vacuo to afford an oil. This oil was purified by flash chromatography (silica, 7 M ammonia in
  • racemic compound 5 was obtained following a synthetic procedure similar to the one reported for the synthesis of compound 1.
  • Compound 5 was separated into the single enantiomers by preparative SFC (Stationary phase:
  • racemic compound 12 was obtained following a synthetic procedure similar to the one reported for the synthesis of compound 1. Purification by Prep SFC (Stationary phase: Chiralpak Diacel AD, 20 x 250 mm, Mobile phase: C0 2 , iPrOH with 0.4% iPrNH 2 ) afforded compound 37 (47 mg, 22%) and compound 186 (50 mg, 24%). EXAMPLE E22 - PREPARATION OF COMPOUNDS 10, 185 AND 38
  • racemic compound 10 was obtained following a synthetic procedure similar to the one reported for the synthesis of compound 1.
  • 1,1 '-Bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (27.82 mg, 0.034 mmol) was added to a solution of Co. No. 40, a mixture of 5-cyclopropyl-3-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-isoxazole [1628832-95-0] and 3-cyclopropyl-5-methyl-4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-isoxazole [1628832-96-1] (178 mg, 0.715 mmol) and CsF (69 mg, 0.454 mmol) in 1,4-dioxane (5 mL) and distilled water (1.25 mL) in a microwave vial under N 2 atmosphere, which was capped and heated under microwave irradiation to 160 °C for
  • Reference to RP HPLC in this example relates to purification using preparative HPLC.
  • Fractions were lyophilised by freeze drying. The gradient profile was adjusted on a per sample basis to maximise resolution between the required compound and any intermediate.
  • the preparative HPLC system consisted of the following components:
  • Gilson FC204 fraction collector set to take 100 x 16 mm tubes
  • HPLC-MS was carried out using an AcquityTM Ultra Performance LC system, comprising a PDA detector, Binary Solvent Manager and SQ detector (Waters UK Ltd., Elstree, UK), tandem linked to a mass spectrometry system (Waters UK Ltd.,
  • phenylboronic acid (5.10 mg, 0.042 mmol) and K2CO3 (1 1.55 mg, 0.084 mmol)) in IPA (0.100 mL), THF (0.100 mL) and water (0.05 mL) loaded into a 250 injection loop and Pd(dppf)Cl2 (1.059 mg, 1.393 mmol) in IPA (0.25 mL) and THF (0.25 mL) loaded to a 250 ⁇ ⁇ injection loop.
  • the material was heated to 140 °C for 10 min in a 2 mL heated coil.
  • the product was passed to an injection valve and purified as described in example E31 , to yield Co. No. 138 (yield 4%).
  • Values are either peak values or melt ranges, and are obtained with experimental uncertainties that are commonly associated with this analytical method.
  • HPLC High Performance Liquid Chromatography
  • MS Mass Spectrometer
  • tune parameters e.g. scanning range, dwell time. ..
  • ions allowing the identification of the compound's nominal monoisotopic molecular weight (MW).
  • Data acquisition was performed with appropriate software.
  • Compounds are described by their experimental retention times (Rt) and ions. If not specified differently in the table of data, the reported molecular ion corresponds to the [M+H] + (protonated molecule) and/or [M-H] ⁇ (deprotonated molecule).
  • SQL Single Quadrupole Detector
  • MSD Mass Selective Detector
  • RT room temperature
  • BEH bridged ethylsiloxane/silica hybrid
  • DAD Diode Array Detector
  • HSS High Strength silica.
  • HPLC-MS was carried out using an AcquityTM Ultra Performance LC system, comprising a PDA detector, Binary Solvent Manager and SQ detector (Waters UK Ltd., Elstree, UK), tandem linked to a mass spectrometry system (Waters UK Ltd.,
  • UV - Diode array over range 220 to 400 nm.
  • the SFC measurement was performed using an Analytical Supercritical fluid
  • SFC chromatography
  • A means first eluting isomer; B means second eluting isomer.
  • J H NMR spectra were recorded on a Bruker Avance III with a 300 MHz Ultrashield magnet, on a Bruker DPX-400 spectrometer operating at 400 MHz, on a Bruker Avance I operating at 500MHz, on a Bruker DPX-360 operating at 360 MHz, or on a Bruker Avance 600 spectrometer operating at 600 MHz, using CHLOROFORM- (deuterated chloroform, CDC1 3 ) or DMSO- 6 (deuterated DMSO, dimethyl-d6 sulfoxide) as solvent. Chemical shifts ( ⁇ ) are reported in parts per million (ppm) relative to tetramethylsilane (TMS), which was used as internal standard.
  • TMS tetramethylsilane
  • the compounds provided in the present invention are inhibitors of the beta-site APP-cleaving enzyme 1 (BACEl).
  • BACEl an aspartic protease
  • AD Alzheimer's Disease
  • BACEl an aspartic protease
  • Abeta beta-amyloid peptides
  • APP beta-amyloid precursor protein
  • APP amyloid precursor protein
  • Compounds of Formula (I) are expected to have their effect substantially at BACEl by virtue of their ability to inhibit the enzymatic activity.
  • the behaviour of such inhibitors tested using a biochemical Fluorescence Resonance Energy Transfer (FRET) based assay and a cellular aLisa assay in SKNBE2 cells described below and which are suitable for the identification of such compounds, and more particularly the compounds according to Formula (I), are shown in Table 8 and Table 9.
  • This assay is a Fluorescence Resonance Energy Transfer Assay (FRET) based assay.
  • the substrate for this assay is an APP derived 13 amino acids peptide that contains the 'Swedish' Lys-Met/Asn-Leu mutation of the amyloid precursor protein (APP) beta-secretase cleavage site.
  • This substrate also contains two fluorophores: (7-methoxycoumarin-4-yl) acetic acid (Mca) is a fluorescent donor with excitation wavelength at 320 nm and emission at 405 nm and 2,4-Dinitrophenyl (Dnp) is a proprietary quencher acceptor. The distance between those two groups has been selected so that upon light excitation, the donor fluorescence energy is significantly quenched by the acceptor, through resonance energy transfer.
  • FRET Fluorescence Resonance Energy Transfer Assay
  • the fluorophore Mca is separated from the quenching group Dnp, restoring the full fluorescence yield of the donor.
  • the increase in fluorescence is linearly related to the rate of proteolysis.
  • aLisa assays In two aLisa assays the levels of Abeta total and Abeta 1-42 produced and secreted into the medium of human neuroblastoma SKNBE2 cells are quantified.
  • the assay is based on the human neuroblastoma SKNBE2 expressing the wild type Amyloid Precursor Protein (hAPP695).
  • the compounds are diluted and added to these cells, incubated for 18 hours and then measurements of Abeta 1-42 and Abeta total are taken.
  • Abeta total and Abeta 1-42 are measured by sandwich aLisa.
  • aLisa is a sandwich assay using biotinylated antibody AbN/25 attached to streptavidin coated beads and antibody Ab4G8 or cAb42/26 conjugated acceptor beads for the detection of Abeta total and Abeta 1-42 respectively.
  • the beads come into close proximity.
  • the excitation of the donor beads provokes the release of singlet oxygen molecules that trigger a cascade of energy transfer in the acceptor beads, resulting in light emission.
  • Light emission is measured after 1 hour incubation (excitation at 650 nm and emission at 615 nm).
  • a best-fit curve is fitted by a minimum sum of squares method to the plot of
  • This assay is a Fluorescence Resonance Energy Transfer Assay (FRET) based assay.
  • the substrate for this assay contains the 'Swedish' Lys-Met/Asn-Leu mutation of the amyloid precursor protein (APP) beta-secretase cleavage site.
  • This substrate also contains two fluorophores: (7-methoxycoumarin-4-yl) acetic acid (Mca) is a fluorescent donor with excitation wavelength at 320 nm and emission at 405 nm and 2,4- Dinitrophenyl (Dnp) is a proprietary quencher acceptor. The distance between those two groups has been selected so that upon light excitation, the donor fluorescence energy is significantly quenched by the acceptor, through resonance energy transfer.
  • FRET Fluorescence Resonance Energy Transfer Assay
  • the fluorophore Mca Upon cleavage by the beta-secretase, the fluorophore Mca is separated from the quenching group Dnp, restoring the full fluorescence yield of the donor.
  • the increase in fluorescence is linearly related to the rate of proteolysis. Briefly in a 384-well format recombinant BACE2 protein in a final concentration of 0.4 ⁇ g/ml is incubated for 450 minutes at room temperature with 10 ⁇ substrate in incubation buffer (50 mM Citrate buffer pH 5.0, 0.05 % PEG, no DMSO) in the absence or presence of compound.
  • a best-fit curve is fitted by a minimum sum of squares method to the plot of %Controlmin versus compound concentration. From this an IC50 value (inhibitory concentration causing 50% inhibition of activity) can be obtained.
  • Base assay buffer was prepared by adding a 50 mM solution of citric acid (1.00244; Merck Biosciences) to stirring solution of 50 mM trisodium citrate (1.06448; Merck Biosciences) until a final pH of 5.0 was achieved.
  • PEG polyethylene glycol
  • base buffer comprised of 50 mM sodium citrate, pH 5.0 containing 0.05% PEG.
  • All assays were routinely carried out in 384-well assay plates (Costar 4514; Corning Life Sciences) and incubated at 37 ⁇ 1°C for 60 min. prior to reading the endpoint fluorescence intensity.
  • the (7-methoxyl coumarin-4-yl)acetic acid based substrate ⁇ -secretase substrate VI was prepared as a 1 mM stock in 100% DMSO (D/4121/PB08; ThermoFisher).
  • Assay buffer was prepared by adding DMSO to base buffer to a final concentration of 1% (vol/vol), ⁇ -secretase I (18.64 ⁇ ; "BACE1”) and ⁇ -secretase II (4.65 ⁇ ; “BACE2”) were obtained from Janssen Pharmaceutica, Beerse, Belgium and were stored as frozen aliquots (-20 ⁇ ) and thawed as required.
  • assay buffer typically 12.5 ⁇ of assay buffer was dispensed to rows B to P of the assay plate.
  • To row A was added 18.75 ⁇ of test compound diluted appropriately in assay buffer.
  • a 6.25 ⁇ aliquot of sample was transferred from row A to row B and the sample mixed three times by pipette. The process was repeated down the plate and 6.25 ⁇ of solution discarded at row N post-mix.
  • Rows O and P were designated as the positive and negative controls.
  • To row P was added 6.25 ⁇ base buffer.
  • 6.25 ⁇ enzyme freshly prepared 40 nM BACE1 or 40 nM BACE2 diluted in base buffer.
  • the fluorescence intensity of the wells was read at 360/405 nm (excitation/emission) utilising a nine reads per well protocol (50 ms integration; density of 3, 0.25 mm spacing; SpectraMAX Paradigm plate reader; TUNE cartridge; SoftMax Pro v 6.3 software; Molecular Devices UK Ltd., Wokingham, Berkshire, UK) and outputting the median value of the nine reads as a text file.
  • Data analysis was carried out using Prism software v 6.3 (GraphPad Inc., San Diego, CA, USA) using the nonlinear regression analysis models supplied by the vendor. For IC50 determinations the four parameter logistic variable slope model was used to fit the raw fluorescence intensity data with the 'bottom' fixed to the negative control.
  • the CyclOps bioassay module consisted of a fraction collection station, a reagent station, liquid handling robotics, plate store and an integrated plate reader
  • the fraction collection station composed of a 384 well collection plate (P-384-240SQ- C; Axygen, Union City, CA, USA) mounted on a H-portal carriage (Festo AG & Co. KG, Esslingen, Germany), a syringe drive and a two-way six port injection valve fitted with a 200 ⁇ loop (VICI AG International, Schenkon Switzerland). The output of the injection valve was addressable to all the positions of a 384 well collection plate.
  • the reagent station consisted of hydraulically cooled (10-12°C) aluminium segments; each manufactured to house a SBS microtiter plate footprint.
  • Probe wash solution (-150 ml; 33.3:33.3:33.3 water:propan-2-ol (P/7508/17; ThermoFisher):methanol (M/4058/17; ThermoFisher) contained in a covered reagent reservoir (390007; Porvair Sciences Ltd., Leatherhead, UK).
  • the liquid handling system composed of a LISSY system (Zinsser Analytik GmbH, Frankfurt, Germany) equipped with gripper arm and single teflon-coated stainless steel probe. Between every liquid handling step the teflon-coated stainless steel probe was washed with probe wash solution followed by system liquid (water). Control of the bioassay system was achieved using WinLISSY software (Zinsser Analytik) and SoftMax Pro (which was under WinLISSY automation command control).
  • a plate store housed a stack of assay plates (Costar 4514). Input and output relays enabled contact closure control and feedback between the bioassay module and the CyclOps control software. The plate store was an aluminium rack that accommodated a stack of assay plates which could be accessed by the liquid handling system.
  • the output of the dilution module flowed through the collection station injection valve set in the 'load' position.
  • WinLISSY set to input polling mode contact closure by the CyclOps control software initiated the bioassay protocol.
  • the first action triggered the injection valve to the 'inject' position, isolating the loop contents, and the fraction collection system dispensed the loop contents to an addressable well on the collection plate.
  • the liquid handling system delivered an assay plate to an assay station on the liquid handling bed. Onto columns of the assay plate the liquid handling system dispensed 12.5 ⁇ assay buffer down two columns of the assay plate from row B to row P. To row A was added 18.75 ⁇ of test compound from the respective well of the collection plate.
  • a 6.25 ⁇ aliquot of sample from row A was transferred to row B. The process was repeated down the plate for both columns and 6.25 ⁇ reagent discarded at row N. Rows O and P were designated as the positive and negative controls.
  • To row P was added 6.25 ⁇ assay buffer.
  • To rows A to O of the first column was added 6.25 ⁇ 40 nM BACE1 stored in base buffer.
  • For the BACE2 enzyme addition 17.5 ⁇ of 400 nM BACE2 was diluted with 157.5 ⁇ base buffer. This was mixed by pipetting 175 ⁇ of solution five times in the designated receiving Eppendorf tube and then 6.25 ⁇ of the diluted BACE2 was added up the respective column.
  • MCA substrate 30.8 ⁇ of 1 mM MCA substrate in 100% DMSO was diluted with 385 ⁇ HPLC water. This was mixed by pipetting 400 ⁇ five times in the designated receiving Eppendorf tube and 6.25 ⁇ added up the respective columns. The assay plate was then transferred to the plate reader carriage, the drawer closed and the assay incubation initiated. After 60 min. WinLISSY executed a sub-routine that instructed the plate reader to load and execute a protocol file which read the fluorescence intensity. This protocol file contained the parameters required to read the microtiter plate and write the corresponding data as a text file.
  • Fluorescence intensity was read at 360/405 nm (excitation/emission) utilising a nine reads per well protocol (50 ms integration; density of 3, 0.25 mm spacing) and outputted the median value of the nine reads as a text file. CyclOps bio assay data analysis

Abstract

La présente invention concerne des inhibiteurs tricycliques de bêta-sécrétase ayant la structure représentée par la formule (I) et (II) ainsi que leurs tautomères et leurs formes stéréoisomères, les radicaux étant tels que définis dans la description. L'invention concerne en outre des compositions pharmaceutiques comprenant ces composés, des procédés de préparation de ces composés et compositions et l'utilisation de ces composés et compositions pour la prévention et le traitement de troubles dans lesquels la bêta-sécrétase est impliquée, tels que la maladie d'Alzheimer (MA), le trouble cognitif léger, la sénilité, la démence, la démence à corps de Lewy, le syndrome de Down, la démence associée à un accident vasculaire cérébral, la démence associée à la maladie de Parkinson, la démence associée à la bêta-amyloïde, la dégénérescence maculaire liée à l'âge, le diabète de type 2 et d'autres troubles métaboliques.
PCT/EP2018/055401 2017-03-07 2018-03-06 Inhibiteurs de bêta-sécrétase WO2018162443A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP18709999.9A EP3592750A1 (fr) 2017-03-07 2018-03-06 Inhibiteurs de bêta-sécrétase
CN201880016454.4A CN110418793A (zh) 2017-03-07 2018-03-06 β-分泌酶的抑制剂
JP2019548602A JP2020509068A (ja) 2017-03-07 2018-03-06 βセクレターゼ阻害剤
CA3051764A CA3051764A1 (fr) 2017-03-07 2018-03-06 Inhibiteurs de beta-secretase
AU2018229721A AU2018229721A1 (en) 2017-03-07 2018-03-06 Inhibitors of beta secretase
US16/489,885 US20200010482A1 (en) 2017-03-07 2018-03-06 Inhibitors of beta secretase
EA201992076A EA201992076A1 (ru) 2017-09-07 2018-03-06 Ингибиторы бета-секретазы
MX2019010649A MX2019010649A (es) 2017-03-07 2018-03-06 Inhibidores de beta secretasa.
KR1020197028598A KR20190126345A (ko) 2017-03-07 2018-03-06 베타 세크레타제의 억제제

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762468052P 2017-03-07 2017-03-07
US62/468,052 2017-03-07
EP17189762 2017-09-07
EP17189762.2 2017-09-07

Publications (1)

Publication Number Publication Date
WO2018162443A1 true WO2018162443A1 (fr) 2018-09-13

Family

ID=59811157

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/055401 WO2018162443A1 (fr) 2017-03-07 2018-03-06 Inhibiteurs de bêta-sécrétase

Country Status (2)

Country Link
EA (1) EA201992076A1 (fr)
WO (1) WO2018162443A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009395A1 (en) * 2009-07-09 2011-01-13 Eli Lilly And Company Bace inhibitors
US20120245155A1 (en) * 2009-12-11 2012-09-27 Shionogi & Co., Ltd. Fused heterocyclic compound having amino group
US20150259308A1 (en) * 2012-10-12 2015-09-17 Amgen Inc. Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009395A1 (en) * 2009-07-09 2011-01-13 Eli Lilly And Company Bace inhibitors
US20120245155A1 (en) * 2009-12-11 2012-09-27 Shionogi & Co., Ltd. Fused heterocyclic compound having amino group
US20150259308A1 (en) * 2012-10-12 2015-09-17 Amgen Inc. Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use

Also Published As

Publication number Publication date
EA201992076A1 (ru) 2020-03-19

Similar Documents

Publication Publication Date Title
AU2012224632B2 (en) 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives useful as inhibitors of beta-secretase (BACE)
CA2819175C (fr) Derives 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine utiles en tant qu'inhibiteurs de beta secretase (bace)
AU2012347397B2 (en) 6-difluoromethyl-5,6-dihydro-2H-[1,4]oxazin-3-amine derivatives
EP3233834B1 (fr) Composés 2,3,4,5-tétrahydropyridine-6-amine et 3,4-dihydro-2 h-pyrrol-5-amine en tant qu'inhibiteurs de la bêta-sécrétase
WO2012117027A1 (fr) Dérivés de 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine utiles en tant qu'inhibiteurs de bêta-sécrétase (bace)
CA2912156C (fr) Derives de 4-amino-6-phenyl-5,6-dihydro-imidazo[1,5-a]pyrazin-3(2h)-one utilises comme inhibiteurs de la beta-secretase (bace)
AU2014280124B2 (en) 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (BACE)
CA3063809A1 (fr) Composes
WO2018162443A1 (fr) Inhibiteurs de bêta-sécrétase
EP3592750A1 (fr) Inhibiteurs de bêta-sécrétase
EP3592751A1 (fr) Inhibiteurs de bêta-sécrétase
WO2018162444A1 (fr) Inhibiteurs de bêta-sécrétase
WO2018162445A1 (fr) Inhibiteurs de bêta-sécrétase
EP3592752A1 (fr) Inhibiteurs de bêta-sécrétase
NZ623858A (en) 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives
NZ623858B2 (en) 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18709999

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3051764

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2018229721

Country of ref document: AU

Date of ref document: 20180306

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019548602

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20197028598

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018709999

Country of ref document: EP

Effective date: 20191007